Dermatology is the branch of medicine that specialises in the study of both normal and abnormal skin and its associated structures. Research and diagnosis of diseases, cancers, cosmetic and ageing conditions of the skin, fat, hair, nails, oral, and genital mucous membranes, are all aspects of dermatology. Healthcare professionals in this area regularly treat patients of all ages presenting with various inflammatory, inherited, environmental, occupational, or malignant skin disorders.
To date, there are approximately 2000 distinct diseases affecting the skin with many variants. Although many skin diseases are harmless and asymptomatic, others are associated with significant disability, increased morbidity, and reduced quality of life.
The dermatologist is involved in the treatment and prevention of a wide range of skin disorders. They employ various investigations to diagnose and medicine-based or surgical interventions to treat various types of skin conditions. These include, but are not limited to, dermatopathology, dermatologic and cosmetic surgery, topical and systemic medicines, immunotherapy, and phototherapy. As well as seeing patients in dermatology clinics, dermatologists act as consultants to other clinical specialists or perform clinical or basic research.
This Dermatology Speciality Hub is an expert educational resource, intended for healthcare professionals, that provides credible medical information in the form of Learning Zones. These Learning Zones provide self-directed medical education about common skin disorders such as skin cancer, urticaria, various types of psoriasis, and atopic dermatitis.
To find out more, navigate through the corresponding Learning Zones.
Related news and insights
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years.
UCB, announced the first presentations of data from the Phase III clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting.
AbbVie announced new late-breaking IMMerge Phase IIIb open-label study head-to-head data showing superior rates of skin clearance for Skyrizi (risankizumab)to Cosentyx (secukinumab) at week 52 in psoriasis. Particularly, 66 percent of psoriasis patients receiving risankizumab achieved completely clear skin (PASI100 in the Psoriasis Area and Severity Index) versus 40 percent of patients receiving secukinumab at week 52 (p<0.001).
In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light–based therapies, which include narrowband and broadband UVB, UVA in conjunction with photosensitizing agents...
This is an executive summary of all consented recommendations of the European Psoriasis Guidelines – Update 2015. The long version of this guideline is available online as supplementary file. A detailed...